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Introduction:  Frozen  section  (FS)  analysis  used  to be the  principal  examination  guiding  surgical  strategy.
The  development  and  recent  standardization  of  ﬁne-needle  aspiration  cytology  (FNAC)  challenges  it as
a systematic  attitude.  The  present  study  assessed  the current  contribution  of  FS, comparing  it  with  FNAC
as a diagnostic  tool guiding  surgery.
Material  and methods:  A  retrospective  diagnostic  study  analyzed  1515  thyroid  samples  over  a  6-year
period.  Two  hundred  and  ﬁfty-two  of  the  patients  had undergone  both  FNAC  (analyzed  in our  unit)  and
FS,  revealing  69  cancers.
Results:  The  sensitivity  and  speciﬁcity  of  FS  and FNAC  were  75.36%  and  100%  versus  31.88% and  100%,
respectively.  In case  of malignancy  on FNAC  (22  patients),  FS  did  not  inﬂuence  indications  for  surgery.
In  case  of non-malignant  FNAC  ﬁndings,  FS  diagnosed  cancer  in  13%  of  cases  (30/230).  In the  subgroup
of  follicular  lesions  (Bethesda  3 and  4),  FS  modiﬁed  surgical  strategy  in only  6.2% of cases  (6/97),  but
diagnosed  13 of  the  16  cancers  (81.25%)  in case  of  Bethesda  5  on FNAC  (21 cases)  and in  9 of  the  13
cancers  (69%)  associated  with  non-diagnostic  FNAC  results  (Bethesda  1: 70 cases).
Conclusion:  Although  its  contribution  is  small,  FS  optimizes  surgery  in  certain  cases.  Systematic  imple-
mentation  may  be economically  justiﬁed,  especially  in  follicular  lesions  diagnosed  on  FNAC,  improving
interpretation  of a difﬁcult  and  operator-dependent  test,  as  is  essential  in certain  FNAC  results.. Introduction
Despite the numerous good practice guidelines in thyroid nod-
le pathology, certain issues such as frozen section (FS) analysis
emain controversial [1–6]. FS is a quick intraoperative micro-
nd/or macroscopic examination involving freezing of a surgical
issue fragment, and is classically the prime guide to surgical exten-
ion [7]. It thus ﬁrst serves to conﬁrm diagnosis and its efﬁcacy can
e assessed in terms of the elimination of false positives so as to
void “over-treatment” (unnecessarily extensive surgery) and of
alse negatives, to limit the risk of “under-treatment” (failure to
erform neck dissection, or 2-step thyroidectomy).
Systematic FS has been challenged for poor cost-effectiveness as
ompared to the widespread use of increasingly effective cytology
echniques for indication in thyroid surgery. Fine-needle aspiration
ytology (FNAC) is non-invasive, simple, reproducible, inexpensive,
ell tolerated and more or less free of complications. It has the great
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advantage over imaging of enabling direct intraoperative morpho-
logic assessment of thyroid tissue. It has become systematic in the
management of nodules, and standardization on the Bethesda clas-
siﬁcation has improved the quality of analysis. Papillary cancer
is thus frequently diagnosed preoperatively; and in other cases,
notably of follicular-type FNAC ﬁndings, FS is often found wanting.
FS, however, is not only an intraoperative examination: it could
be the keystone in a novel concept of integrative pathology [8–10];
fresh thyroid specimens can serve not only for FS analysis but also
for biobanking [11–13].
Fresh thyroid specimens sampled for FS analysis can thus
provide short-term beneﬁt by “real-time” adaptation of surgery,
and also a longer term contribution from molecular biology analysis
based on a biobank.
In the context of this new integrative approach, the present
study compared FS and FNAC as diagnostic tests guiding surgery.
2. Materials and methodsA retrospective experimental diagnostic study included all thy-
roid specimens sampled for FS analysis and included in the center’s
biobank between September 1st, 2004 and December 31st, 2010.
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Table 1
Cytology-histology equivalences.
Bethesda
terminology
Number of cases
n (%)
Malignant FS n (%) Malignancy on
deﬁnitive histology
n (%)
Malignancy rate in
literature
(%) [15]
Bethesda 1
(non-diagnostic)
70(27.8) 9(69) 13(18.6) 1–4
Bethesda 2 (benign) 42(16.7) 2(4.7) 2(4.7) 0–3
Bethesda 3
(follicular lesion of
indeterminate signiﬁcance)
14(5.6) 0(0) 2(14.3) 5–15
Bethesda 4
(follicular neoplasm or
suspicious for Hürthle-cell
neoplasm)
83(32.9) 6(42.9) 14(16.9) 15–30
(81.3
(100)
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(suspicious for malignancy)
21(8.3) 13
Bethesda 6 (malignant) 22(8.7) 100
.1. Selection for surgery
Our patient selection criteria were based on the national and
nternational guidelines available at the time [1], and the team’s
wn experience [14]. A single surgical strategy founded on clearly
odiﬁed indications could thus be implemented as of 2004. Three
roups of indications were distinguished: mechanical complica-
ions (head and neck axis compression), hyperthyroidism (isolated
odule or multinodular goiter) and suspected cancer (or “nodule at
isk of cancer”).
The third group comprised of asymptomatic patients for whom
he risk of cancer associated with a nodule or nodules was to be
ssessed. Since 2006, our diagnostic strategy was standardized,
ividing this group between mandatory and theoretic indications
or surgery. Mandatory indications were ranked according to 3
actors: biological results with elevated calcitoninemia (> 10 ng/l)
uggestive of thyroid medullary carcinoma, cytology with malig-
ant or suspect FNAC samples, and clinical with hard nodule or
uspect cervical adenopathy on palpation. In theoretic indications,
here were no elements making surgery obligatory and few if any
actors of malignancy; surveillance including FNAC was  proposed
nd the risk/beneﬁt ratio was discussed in consultation with the
atient and in multidisciplinary team meeting.
Factors of malignancy were based on the classical litera-
ure data: predisposition involving age < 25 years, male gender,
mmunosuppression, and history of cervical irradiation or familial
istory of thyroid cancer. Ultrasound ﬁndings were also taken into
ccount: full hypoechogenic nodule, irregular contours, microcal-
iﬁcations, absence of nodular halo, signs of extracapsular invasion
nd nodular vascularization.
Prior to the 2008 NCI/Bethesda cytopathology system [15], a
our-fold classiﬁcation was used: benign, non-diagnostic, follicular
nd suspect. When cytology suggested a follicular lesion, surgery
as frequently proposed on theoretic grounds, weighted by other
linical and ultrasonographic ﬁndings.
After 2008 and the routine adoption of the NCI/Bethesda system
15], our therapeutic attitude was adapted to the consensual guide-
ines. In “follicular lesions of indeterminate signiﬁcance” (Bethesda
), FNAC was repeated under ultrasound guidance at 3–6 months,
ith surgery indicated in case of a second indeterminate result.
n “follicular neoplasm or suspicious for Hürthle-cell neoplasm”
Bethesda 4), surgery was systematically proposed.
.2. Frozen section analysisThe FS arrived by the pneumatic tube transport system between
he operating theater and the laboratory macroscopy room. The
hysician performed timely macroscopic examination and entered) 16(76.2) 60–75
 22(100) 97–99
the results (specimen quality, anatomic location, size, weight,
and location of principal and associated lesions) on standardized
macroscopy forms. Macroscopically suspect regions were placed on
a support covered with CryomatrixTM resin, and cut into 5 m slices
after freezing in a cryostat (LEILA CM 1950). Rapid staining (car-
bolic toluidine blue and differentiation in water) was performed
for microscopic examination. Imprint cytology was also performed
at the pathologist’s discretion. Results were communicated orally
to the surgeon and also entered on a dedicated FS form faxed to
theater: patient ID, date and time of specimen arrival, ordering
department, type of sample, number of samples and of imprints, FS
analysis ﬁndings, contact with theater receiving the result, name of
pathologist. Results were of 3 types: benign lesion, malignant lesion
or diagnosis pending. Histologic tumor type was speciﬁed when-
ever possible. After thawing and ﬁxation in 10% formaldehyde, the
specimen and the non-frozen part of the specimen were included
in parafﬁn for deﬁnitive diagnosis on HES staining.
2.3. Freezing of fresh thyroid tissue
Following FS analysis, the pathologist decided whether to con-
serve the specimens by freezing. Sample region topography, weight
and time to freezing were entered on standardized forms with 2
mirror-image samples of lesion and perilesional tissue. The clinical
and pathology data were stored in a database (Cresalys Software;
Alphelys, Paris, France), a part of which was put on-line on the
biobank website (www.biobank06.com).
2.4. Thyroid FNAC samples
From 2004 to 2009, a number of thyroid samples were taken by
ﬁne-needle aspiration. Cytology samples from before 2008 were
reclassiﬁed on the new NCI/Bethesda system [15], based on cytol-
ogy reports or re-reading of slides by the original pathologists who
had recorded the initial results. Data were collected using Clini-
com Siemens Health Services and Apix software, used for patient
databases in our center.
All data were entered under Excel: ID number, date of birth,
gender, sample type, FS result, deﬁnitive histologic diagnosis,
pathologist’s name and results of thyroid FNAC performed in the
center.
FS and FNAC data were compared as follows. FS analysis was
considered positive only in case of malignancy; benign and post-
poned diagnoses were both counted as negative, as surgery was
in both cases suspended awaiting deﬁnitive histologic diagnosis.
Likewise, malignant FNAC results were considered positive only
when they indicated extensive surgery; all others were counted
as negative. Histologically indeterminate tumors were counted as
N. Guevara et al. / European Annals of Otorhinolaryngo
Table  2
Sensitivity (Se), speciﬁcity (Sp), positive predictive value (PPV) and negative predic-
tive  value (NPV) for FS and FNAC.
Se (%) Sp (%) PPV (%) NPV (%)
FS (n = 1515) 78.3 100 100 94.8
FS  (n = 252) 75.4 100 100 91.5
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cFNAC (n = 252) 31.9 100 100 79.6
on-pathological, as their status is a matter of debate [16]. Patients
ith FNAC results from outside our unit were not included in com-
arative analysis.
. Results
From September 1st, 2004 to December 31st, 2010, 1515
atients operated on for thyroid pathology had FS analysis and con-
ented to the storage and use of their samples and derivatives in
he biobank. Two hundred and ﬁfty-two had both FS and FNAC.
Tables 1 and 2 show sensitivity (Se), speciﬁcity (Sp), positive
redictive value (PPV) and negative predictive value (NPV) for FS
nd FNAC.
Results for FS on 1515 specimens were Se 78.3%, Sp 100%, PPV
00%, and NPV 94.8%.
In the “non-diagnostic” (Bethesda 1) category (27.8%), FS diag-
osed 69% (9/13) of cancers (Fig. 1). On deﬁnitive histology, the
alignancy rate in this category was 18.6% (13/70): 10 papillary
arcinomas, 1 follicular carcinoma with minimal invasion, 1 poorly
ifferentiated carcinoma, and 1 medullary carcinoma.
In the “benign” (Bethesda 2) category (16.66%), FS detected 2
alse negatives (Fig. 1); 4.7% (2/42): both papillary carcinomas.
In the “follicular of indeterminate signiﬁcance” (Bethesda 3) cat-
gory (5.55%), FS failed to diagnose any malignancies. On deﬁnitive
istology, the malignancy rate in this category was 14.3% (2/14): 1
apillary and 1 follicular carcinoma.
In the “follicular neoplasm or suspicious for Hürthle-cell neo-
lasm” (Bethesda 4) category (32.9%), FS diagnosed 42.9% (6/14)
f cancers: all follicular variants of papillary thyroid carcinoma
FVPTC) (Fig. 1). On deﬁnitive histology, the malignancy rate in this
ategory was 16.9% (14/83): 11 FVPTCs and 3 follicular carcinomas.
In the “suspicious for malignancy” (Bethesda 5) category (8.4%),
S diagnosed 81.3% (13/16) of cancers (Fig. 1). On deﬁnitive his-
ology, the malignancy rate in this category was 76.2% (16/21): 15
apillary carcinomas and 1 lymphoma.
In the “malignant” (Bethesda 6) category (8.7%), FS detected all
2 malignancies: 15 papillary carcinomas and 7 thyroid medullary
arcinomas.
56%
25%
15%
2%
2%
PC
FVPTC
Medullary C
Follicular C
Poorly
differentiated C
ig. 1. Incidence of types of neoplasm diagnosed on frozen section.
C: papillary carcinoma; FVPTC: follicular variant of papillary thyroid carcinoma; C:
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4. Discussion
The present study showed FS to make only a slight diagnostic
contribution in thyroid pathology, although in some cases it does
complement FNAC, enabling 1-step surgery [17]. From Table 2, it
may  seem that FS performs better than FNAC, with higher sen-
sitivity and negative predictive value. However, these represent
overall results, not distinguishing between FNAC diagnosis of follic-
ular and papillary lesions. To be more exact, FS diagnosed only 13%
of neoplasms in case of non-malignant FNAC ﬁndings. Focusing on
follicular lesions (Bethesda 3 and 4), FS modiﬁed surgical strategy
in only 6.2% of cases.
As FNAC becomes more or less systematic, should FS be reserved
to certain types of FNAC ﬁndings?
In the present study, FNAC showed high speciﬁcity (100%) but
lower sensitivity (31.9%); corresponding ﬁgures in the literature
vary, with ranges of respectively 72–100% and 65–98%, depending
on the team. [18]. The present low sensitivity for FNAC was due
to malignant results being counted positive only when indicating
extensive surgery. Low sensitivity in general is partly due to the
non-deﬁnitive FNAC categories: “follicular of indeterminate sig-
niﬁcance”, “suspicious of malignancy” and “suspicious of follicular
neoplasm”. Bias in selection for FNAC, use of ultrasound guidance
or not, numerous follicular neoplasm ﬁndings indicating surgery
on theoretic grounds and confounding factors in histology or FNAC
diagnosis may  also contribute to variability. Analysis of the present
FNAC results in terms of prediction of malignancy on the Bethesda
system nevertheless shows them to be in line with the literature
(Table 2).
In the present study, FS was  also less sensitive (75.4%), but highly
speciﬁc (100%); corresponding ﬁgures in the literature vary, with
mean values of respectively 71% and 98% [3]. Variation between
studies is generally due to defects of sampling (nodule calciﬁcation)
or of interpretation. To limit the risk of false positives for papil-
lary carcinoma, especially when FVPTC, extemporaneous imprint
cytology may  be useful.
NPV was higher for FS than for FNAC in the present study (91.5%
versus 79.6%), suggesting that FS may  limit reoperation in a certain
number of cases.
False negatives in FNAC generally result from deﬁciencies in
lesion sampling, technique (cell ﬁxation, staining and conserva-
tion) or amount of material (hemorrhage, cyst). False negatives
concern the “non-diagnostic” category, which varies from 3% to 31%
between reports, with neoplasm rates assessed at 1–4% [15]. In this
category, FNAC has to be repeated, with surgery in case of recur-
rent non-diagnostic results. FS proved useful here, diagnosing 69%
of cancers and improving surgical strategy.
There is also a risk of false negatives in the “benign” FNAC cat-
egory, which makes up most of the results (> 90%), with a lower
malignancy rate (4.7% in the present study; 0–3% in the literature
[15]). In the present study, FS detected false negatives, enabling
total thyroidectomy and neck dissection in a single step, in only 2
cases. This low cost-effectiveness is one argument brought against
the practice of FS by some authors [15].
The “suspicious of malignancy” category, in which diagnos-
tic criteria of malignancy are incomplete, involves a malignancy
rate reported to be 50–75%. The recommended attitude is surgi-
cal: lobectomy or total thyroidectomy. FS thus seems necessary
before deciding on extensive surgery [15], showing good sensitivity
(81.3%) in this category.
FS may  not be required when FNAC is positive for malignancy,
as in 3–7% of cases. The speciﬁcity and PPV of both FNAC and FS
are excellent: 100% in the present study and > 95% in the literature
[3]. But it is precisely in such cases of neoplasm that analysis and
cryopreservation of fresh specimens for biobanking comes into its
own.
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In the “follicular neoplasm or suspicious for Hürthle-cell neo-
lasm” category, surgery is preferable, as there are no cytologic
riteria speciﬁc to follicular carcinoma, which can only be diag-
osed by histologic evidence of capsular and/or follicular invasion.
his cannot be assessed on FNAC, which thus cannot distinguish
etween benign and malignant follicular neoplasms. In this cat-
gory, surgical exploration is required, and ﬁnds only 12–32% of
esions to be malignant (mainly FVPTC, with less than 5% follicular
arcinomas [15]). Malignancy is very hard to diagnose in follicular
esions on FS, as capsule rupture and/or vascular embolism, which
re the diagnostic criteria for follicular carcinoma, are rarely found;
 large tumoral specimen is usually required for deﬁnitive analysis.
ikewise, the nuclear criteria for FVPTC are not visible on FS [15].
he contribution of FS here has been questioned [3,15,19–25] due
o its poor sensitivity: 3–15% in the literature [15]. Nor did FS prove
ontributive in the “follicular of indeterminate signiﬁcance” cate-
ory, a heterogeneous category comprising lesions showing certain
odiﬁcations but insufﬁcient to warrant a diagnosis of “suspicious
f follicular neoplasm” or “suspicious of malignancy”. The “follicu-
ar of indeterminate signiﬁcance” category should not exceed 3–6%
f FNAC results, as only 5–15% prove malignant on histology [15],
n line with the present malignancy rate of 14.3%. In both these
ituations, FS is poorly contributive, optimizing individual manage-
ent (enabling 1-step surgery) in only 6.2% of cases. The economic
nterest of systematic FS analysis is thus a legitimate question, espe-
ially for isolated FS intended purely to guide surgery: the risk of
under-treatment” is to be weighed against the cost of FS. On the
ther hand, if FS is part of a global strategy of integrative pathol-
gy associated to FNAC, the question no longer arises. FS, as well as
omplementing FNAC, allows immediate individual optimization
f surgery in some cases and, over the longer term, contributes
o individual and collective optimization of thyroid biopathology:
olecular biology, prognosis and the emergence of targeted ther-
pies.
Moreover, thyroid surgery may  often be indicated without
rior FNAC. Some patients refuse FNAC, while some clinically or
ltrasonographically highly suspect nodules may  be operated on
ithout diagnostic FNAC. Finally, in some cases the multiplicity of
odules, their particular location or else particular patient-related
actors may  prevent FNAC. FS may  then serve to guide surgery.
In an integrative approach, FS thus becomes a systematic atti-
ude. In the present study, the overall efﬁcacy of FS was  very good,
otably showing 78% sensitivity, which was much better than in
ertain other reports [25]. It remains, however, a difﬁcult and
perator-dependent examination. Systematic FS for biobanking
hould improve the learning curve of interpretation by repetition
nd continual histologic feedback. This is a further argument for the
ptimization of overall management of thyroid nodule pathology
nder a concept of integrative pathology.
. ConclusionHowever slight its contribution, FS complements FNAC in
ntraoperative diagnosis, optimizing individual management by
nabling 1-step surgery. Systematic FS is a legitimate subject of eco-
omic discussion, especially in the subgroup of follicular lesions.
[
[logy, Head and Neck diseases 132 (2015) 67–70
Systematic implementation would improve the quality of an exam-
ination, which is in fact indispensable in the case of certain FNAC
results (Bethesda 5 and 1).
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